The third generation of left ventricular assist devices (LVADs) has been shown to improve outcome and quality of life in patients suffering from acute and chronic heart failure. However, VAD-associated complications are still a challenge in the clinical practice. Here we report the resolution of a mobile thrombus formation in the proximity of the inflow cannula of a third generation of LVADs (HVAD Pump, HeartWare, Inc.) in a patient with chronic heart failure 4 months after implantation
Includes bibliographical references (pages 75-80).Heart transplantation remains the primary treatmen...
Thromboembolic events occur in 2–3 % of patients receiving the HeartMate II ™ (HMII) left ventricula...
Left Ventricular Assist Devices (LVADs) are becoming a more widely accepted form of treatment for pa...
Copyright © 2012 Jens Garbade et al. This is an open access article distributed under the Creative C...
AbstractHeart failure is one of the leading causes of mortality and morbidity in the world. Heart tr...
AbstractThe left ventricular assist device (LVAD) is a battery-operated, mechanical pump-type device...
Mechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are ve...
The use of left ventricular assist devices (LVADs) in themanagement of advanced heart failure has gr...
Left ventricular assist devices (LVADs), more importantly the continuous-flow subclass, have revolut...
Background: Pump thrombosis (PT) is a dreaded complication after left ventricular assist device (LVA...
Even if the HeartMate 3TM left ventricular assist device is associated with excellent outcomes, comp...
The Jarvik 2000 Flowmaker® is an implantable left-ventricular assist device (LVAD) that produces axi...
Background Despite numerous design iterations, thrombus formation at the inflow cannula of continuo...
Pump thrombosis is a devastating complication after left ventricular assist device implantation. Thi...
Over the past decade, left ventricular assist device (VAD) therapy has become more prevalent and inc...
Includes bibliographical references (pages 75-80).Heart transplantation remains the primary treatmen...
Thromboembolic events occur in 2–3 % of patients receiving the HeartMate II ™ (HMII) left ventricula...
Left Ventricular Assist Devices (LVADs) are becoming a more widely accepted form of treatment for pa...
Copyright © 2012 Jens Garbade et al. This is an open access article distributed under the Creative C...
AbstractHeart failure is one of the leading causes of mortality and morbidity in the world. Heart tr...
AbstractThe left ventricular assist device (LVAD) is a battery-operated, mechanical pump-type device...
Mechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are ve...
The use of left ventricular assist devices (LVADs) in themanagement of advanced heart failure has gr...
Left ventricular assist devices (LVADs), more importantly the continuous-flow subclass, have revolut...
Background: Pump thrombosis (PT) is a dreaded complication after left ventricular assist device (LVA...
Even if the HeartMate 3TM left ventricular assist device is associated with excellent outcomes, comp...
The Jarvik 2000 Flowmaker® is an implantable left-ventricular assist device (LVAD) that produces axi...
Background Despite numerous design iterations, thrombus formation at the inflow cannula of continuo...
Pump thrombosis is a devastating complication after left ventricular assist device implantation. Thi...
Over the past decade, left ventricular assist device (VAD) therapy has become more prevalent and inc...
Includes bibliographical references (pages 75-80).Heart transplantation remains the primary treatmen...
Thromboembolic events occur in 2–3 % of patients receiving the HeartMate II ™ (HMII) left ventricula...
Left Ventricular Assist Devices (LVADs) are becoming a more widely accepted form of treatment for pa...